Subscribe to RSS
DOI: 10.1055/s-0036-1593823
Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease
Publication History
Publication Date:
24 October 2016 (online)
Abstract
In patients with acute coronary syndrome, high platelet reactivity (PR) is associated with an increased risk of secondary thrombotic events. However, in patients undergoing elective percutaneous coronary intervention (PCI), no association between high PR and outcome has been demonstrated. At present, the relation of PR and clinical symptoms is unknown.
To examine the association of PR with clinical indication for diagnostic angiography (stable or unstable coronary artery disease [CAD]), taking into account the influence of P2Y12 inhibitors.
A platelet function score (PFS) was determined in 195 patients by quantifying fibrinogen binding and P-selectin expression with flow cytometry. We evaluated the PFS with clinical presentation of stable or unstable CAD, angiographic severity of CAD, and the incidence of cardiovascular events during 2 years of follow-up. All data were analyzed stratified by P2Y12 inhibitor use (long-term and preprocedural versus none).
Surprisingly, among non-P2Y12 inhibitor users, the PFS was lower in patients with unstable CAD compared with stable CAD (5.6 ± 1.8 vs. 7.4 ± 1.6; p = 0.001). Angiographic CAD severity showed no relation with PFS. The SYNTAX score tended to be inversely related with PFS: low PFS, 13.2 (IQR, 11.9–19.1); median PFS, 10.0 (IQR, 5.0–14.0); and high PFS, 8.0 (IQR, 5.0–13.0), without significance (p = 0.304). Patients with low PFSs required more re-PCIs than those with median and high PFSs (11.1 vs. 4.7 vs. 0.0%, p = 0.004). This association was modified for patients using P2Y12 inhibitors.
Among patients without P2Y12 inhibitors undergoing coronary angiography, presentation of unstable CAD is independently associated with lower PR.
Keywords
P2Y12 inhibitor - platelet reactivity testing - coronary artery disease - coronary angiography - high on-treatment platelet reactivity - platelet function testing - flow cytometry* Both the authors contributed equally to this manuscript.
-
References
- 1 Nuyttens BP, Thijs T, Deckmyn H, Broos K. Platelet adhesion to collagen. Thromb Res 2011; 127 (Suppl. 02) S26-S29
- 2 Montalescot G, Sechtem U, Achenbach S , et al; Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38) 2949-3003
- 3 Hamm CW, Bassand JP, Agewall S , et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (23) 2999-3054
- 4 Steg PG, James SK, Atar D , et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
- 5 Janssen PW, ten Berg JM, Hackeng CM. The use of platelet function testing in PCI and CABG patients. Blood Rev 2014; 28 (3) 109-121
- 6 Breet NJ, van Werkum JW, Bouman HJ , et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303 (8) 754-762
- 7 de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative group of the primary prevention project. Lancet 2001; 357: 89-95
- 8 Montalescot G, Wiviott SD, Braunwald E , et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373 (9665) 723-731
- 9 Wisman PP, Roest M, Asselbergs FW , et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (5) 736-747
- 10 Tantry US, Bonello L, Aradi D , et al; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62 (24) 2261-2273
- 11 Piccolo R, Galasso G, De Luca G , et al. Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: a meta-regression analysis of 30 randomized trials. Atherosclerosis 2014; 234 (1) 176-184
- 12 Thygesen K, Alpert JS, Jaffe AS , et al; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012; 126 (16) 2020-2035
- 13 Roest M, van Holten TC, Fleurke GJ, Remijn JA. Platelet activation test in unprocessed blood (pac-t-ub) to monitor platelet concentrates and whole blood of thrombocytopenic patients. Transfus Med Hemother 2013; 40 (2) 117-125
- 14 ten Berg MJ, Huisman A, van den Bemt PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007; 45 (1) 13-19
- 15 Sianos G, Morel MA, Kappetein AP , et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1 (2) 219-227
- 16 Généreux P, Palmerini T, Caixeta A , et al. SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. Circ Cardiovasc Interv 2011; 4 (6) 553-561
- 17 Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing; 2013
- 18 Sestito A, Maccallini A, Sgueglia GA , et al. Platelet reactivity in response to mental stress in syndrome X and in stable or unstable coronary artery disease. Thromb Res 2005; 116 (1) 25-31
- 19 Milovanovic M, Fransson SG, Richter A, Järemo P. Inverse relationships between coronary blood flow obstruction and platelet reactivity in stable angina pectoris. Platelets 2005; 16 (3–4) 211-213
- 20 Cassar K, Bachoo P, Ford I, Greaves M, Brittenden J. Platelet activation is increased in peripheral arterial disease. J Vasc Surg 2003; 38 (1) 99-103
- 21 Chistiakov DA, Orekhov AN, Bobryshev YV. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol (Oxf) 2015; 213 (3) 539-553
- 22 Przyklenk K, Whittaker P. Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. Circulation 2000; 102 (1) 88-95
- 23 Muller DW, Topol EJ, Califf RM , et al; Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1990; 119 (2 Pt 1): 224-231
- 24 Linden MD, Whittaker P, Frelinger III AL, Barnard MR, Michelson AD, Przyklenk K. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost 2006; 4 (12) 2670-2677
- 25 Nenci GG, Berrettini M, Todisco T, Costantini V, Grasselli S. Exhausted platelets in chronic obstructive pulmonary disease. Respiration 1983; 44 (1) 71-76
- 26 Mannucci PM, Cattaneo M, Canciani MT, Maniezzo M, Vaglini M, Cascinelli N. Early presence of activated (‘exhausted’) platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). Eur J Cancer Clin Oncol 1989; 25 (10) 1413-1417
- 27 Jurk K, Jahn UR, Van Aken H , et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91 (2) 334-344
- 28 Droppa M, Tschernow D, Müller KA , et al. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). PLoS One 2015; 10 (3) e0121620
- 29 Wisman PP, Teraa M, de Borst GJ, Verhaar MC, Roest M, Moll FL. Baseline platelet activation and reactivity in patients with critical limb ischemia. PLoS One 2015; 10 (7) e0131356
- 30 Siasos G, Oikonomou E, Zaromitidou M , et al. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel. Int J Cardiol 2014; 177 (1) 192-196